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Hepatic ferredoxin (hepatoredoxin) was purified from bovine liver mitochondria. The monomeric molecular 
mass of the hepatoredoxin was larger than that of adrenocortical ferredoxin (adrenodoxin) from bovine 
adrenocortical mitochondria at 14 kDa. We studied the amino acid residues and NH,-terminal sequence 
of this protein. The hepatoredoxin was organ-specific protein. The optical absorption spectrum of oxidized 
hepatoredoxin had two peaks, at 414 and 455 nm in the visible region. Hepatoredoxin formed an immuno- 
precipitin line against anti-adrenodoxin immunoglobulin in Ouchterlony double diffusion, and an immuno- 
chemical staining band in Western blotting. 
Ferredoxin Iron-sulfur protein Nonheme iron protein Cytochrome P-450-linked monooxygenase 
(Bovine liver) Mitochondrial 
1. INTRODUCTION 
Ferredoxin in mammalian tissues is a component 
of the monooxygenase system linked with 
cytochrome P-450 in mitochondria [l-4]. 
NADPH-ferredoxin reductases of cattle are organ- 
specific and the hepatic ferredoxin from bovine 
hepatocytes has been tentatively named hepato- 
redoxin [5,6]. We purified hepatoredoxin from 
bovine liver mitochondria and characterized it 
biochemically. Here, we discuss the amino acid 
residues, molecular mass, immunochemical prop- 
erties and amino-terminal sequence of this protein. 
Hepatoredoxin was compared with bovine 
adrenocortical ferredoxin (adrenodoxin). 
2. MATERIALS AND METHODS 
2.1. Materials 
Livers of 3-year-old Holstein-Friesian cattle 
were obtained from a local slaughterhouse, chilled 
on ice and brought immediately to the laboratory. 
The livers were perfused with ice-cold 1.15 M KC1 
solution adjusted with 1 M Tris to pH 7.4 to 
Cytochrome P-4.50-oxygenase system 
remove blood through the portal vein. Fat, con- 
nective tissue and the main blood vessels were 
carefully removed. The liver was then cut into 
small pieces and homogenized in 5 vols ice-cold 
0.25 M sucrose solution adjusted with 1 M Tris 
solution to pH 7.4. The mitochondrial fraction of 
the liver was prepared using the method of Hatefi 
and Lester [7]. 
2.2. Enzyme assays 
The activity of hepatoredoxin was measured in 
the presence of NADPH-adrenodoxin reductase 
and cytochrome c as the activity of NADPH- 
cytochrome-c reductase, by the method of 
Hiwatashi et al. [8]. 
2.3. Protein 
Protein was assayed by the method of Lowry et 
al. [9] or by the biuret reaction [IO], using bovine 
serum albumin as the standard. 
2.4. Amino acid anaiysis 
The amino acid residues were analyzed as 
described elsewhere [8] on a Hitachi 835 amino 
acid analyzer. 
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2.5. Sequence of amino acid residues 
We determined the sequence of amino acid 
residues on an Applied Biosystems, model 47OA, 
sequencer. 
2 6. Electrophoresis 
SDS-polyacrylamide slab gel electrophoresis was 
done by the method of Laemmli [l I]. Bovine 
adrenodoxin (12.5 kDa), horse heart cytochrome c 
(12.4 kDa), soybean trypsin inhibitor (20.1 kDa), 
carbonic anhydrase (30 kDa), ovalbumin (43 
kDa), and bovine serum albumin (67 kDa) were 
used as the standard proteins. 
2.7. Serology and immunochemistry 
Antibody to adrenodoxin was prepared as in [2] . 
The Ouchterlony double diffusion test was done 
on a slide glass covered with 1.0% (w/v) agar in 
0.86% (w/v) NaCl solution containing 0.02% 
(w/v) NaN3. The center well was filled with the an- 
tibody to adrenodoxin and the outer wells with 
bovine hepatoredoxin and adrenodoxin. The agar 
plate was placed in a dark box at 4°C for 2 days. 
Wells were 3 mm in diameter and the center to 
center distance between the antigen and the an- 
tibody wells was 5 mm. 
2.8. Western blotting 
The amount of hepatoredoxin was estimated im- 
munochemically using varjous concentrations of 
bovine adrenodoxin as the standard, by the 
method of Towbin et al. [ 121. 
2.9. Reconstitution of 25 and 2Phydroxyiations 
of steroids 
Reconstitutions of 25 and 27-hydroxylations of 
cholecalciferol and 5-cholestane-3,7,12-trio1 were 
done as described in [2] and according to Atsuta 
and Okuda 1131, respectively. 
2.10. Chemicals 
The chemical reagents used were of the highest 
grade commercial!y available. 
3. RESULTS 
The concentration of hepatoredoxin in the liver 
was 0.09 zf: 0.01 nmol/mg protein. That of 
adrenodoxin in adrenocortices was 2.65 + 
88 
0.07 nmol/mg protein. There was 3-4% as much 
hepatoredoxin as adrenodoxin. 
Purification of hepatoredoxin was done at 
0-4°C. Mitochondria were suspended in 10 mM 
Na-phosphate buffer, pH 7.4. The solution (16 mg 
protein/ml x 7300 ml) was homogenized twice for 
5 min using a Matsushita homogenizer (model 
MX-150S), and the solution was sonicated by a 
Waken sonicator (model W-225R) for a total of 
10 min. The sonicated mitochondria were cen- 
trifuged at 65000 x g for 90 min in a refrigerated 
Hitachi 55~ ultracentrifuge with a refrigerated bar- 
rel rotor. The brown supernatant was put on a 
DEAE-cellulose column (5 x 29 cm) equilibrated 
with 30 mM K-phosphate buffer, pH 7.4. The col- 
umn was washed with 1 1 of 30 mM K-phosphate 
buffer. Next, the active fraction of hepatoredoxin 
was eluted with 50 mM K-phosphate buffer, pH 
7.4, containing 0.13 M KCl. The eluted solution 
was diluted with the same volume of 50 mM K- 
phosphate buffer, pH 7.4, and put on a DEAB- 
cellulose column (2.9 x 15 cm) equilibrated with 
50 mM K-phosphate buffer, pH 7.4. The column 
was washed with 50 mM K-phosphate buffer, pH 
7.4, containing 60 mM KC1 and the sample eluted 
with 50 mM K-phosphate buffer, pH 7.4, contain- 
ing 0.3 M KCl. The eluted solution was diluted 
with a 2.5-fold volume of 50 mM K-phosphate 
buffer, pH 7.4, and put on a DEAE-cellulose col- 
umn (1.7 x 10 cm) equilibrated with 50 mM K- 
phosphate buffer, pH 7.4. The column was washed 
with 50 mM K-phosphate buffer, pH 7.4, contain- 
ing 86 mM KCl. The sample was eluted with 
50 mM K-phosphate buffer, pH 7.4, containing 
0.4 M KCl. The eluted solution was dialyzed 
against 50 mM K-phosphate buffer, pH 7.4, and 
used as the partial purified hepatoredoxin. 
The optical absorption spectrum of the partial 
purified hepatoredoxin is shown in fig. 1. The solu- 
tion contained hepatoredoxin with strong activity 
of NADPH-cytochrome-c reductase in the 
presence of NADPH-adrenodoxin reductase. The 
spectrum of oxidized hepatoredoxin had peaks at 
414 and 455 nm in the visible region. The reduced 
form did not absorb light. The hepatoredoxin solu- 
tion was studied by SDS-polyacrylamide gel elec- 
trophoresis. The main protein band was at 14 kDa 
and some contaminants were found on the slab gel. 
We found by Western blotting that the main pro- 
tein band is identical with hepatoredoxin. This 
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Fig. 1. Absolute optical absorption spectrum of oxidized 
hepatoredoxin in the visible region. The cuvette 
contained 30 .&I hepatoredoxin in 0.1 M K-phosphate 
buffer, pH 7.4, at 25°C. 
band of hepatoredoxin was obtained by 
preparative electrophoretic fractionation. The 
solution of hepatoredoxin was lgophilized before 
study on the amino acid analyzer and sequencer. 
The lyophilized preparation was seen elec- 
trophoretically and immunochemically to be a 
single protein band and a single immunochemical 
staining band against nitrocellulose sheet. The 
results and densitometric scanning patterns are 
shown in fig.2. The monomeric molecular mass of 
hepatoredoxin was estimated electrophoretically to 
be 14 kDa (fig.3). 
The amino acid composition and amino- 
terminal sequence of the hepatoredoxin are given 
in table 1. Larger amounts of Glx and Pro and 
small amounts of Asx, Thr, Ile, His, and Arg were 
present. 
Ouchterlony double diffusion was done to com- 
pare adrenodoxin with hepatoredoxin. The results 
of the Ouchterlony double diffusion test are in 
fig.4. In the test, an immunochemical precipitin 
line against he antibody to adrenodoxin was form- 
ed. Spur formation between hepatoredoxin and 
adrenodoxin was not seen, although the amino 
acid residue composition and the NHz-terminal se- 
quence of hepatoredoxin differed from those of 
adrenodoxin. 
Purified hepatoredoxin was useful for the 
reconstitution of 25 and 27-hydroxylations of 
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Fig.2. (a) 1, electrophoretic pattern of hepatoredoxin on 
SDS-polyacrylamide gel. The slab gel received 5 cg 
hepatoredoxin. Lanes: A, crude hepatoredoxin; B, 
purified hepatoredoxin; C, bovine adrenodoxin. 2, 
immunochemical staining nitrocellulose sheet of samples 
A, B and C. (b) Densitometric scanning patterns of the 
slab gel [(a), 11. 
steroids such as cholecalciferol, cholestanediol, 
cholestanetriol and dihydroxycholestenone (not 
shown). 
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Fig.3. Estimation of the monomeric molecular mass of 
hepatoredoxin by SDS-polyacrylamide g l electropho- 
resis using 15(rlo (w/v) acrylamide. The amount of the 
sample and marker proteins was 5 rg each. (0) Hepato- 
redoxin, (0) marker proteins. 
Table 1 Adrenodoxin 
Amino acid composition and amino-terminal sequence 
of hepatoredoxin 
Sbr-Ssr-Ser-Gin-A:p-Ly.- lie-Thr-“al& 
Pk- I I.-A,“-A,g-A~~-Gly-Glu- 
Composition Residue/ NH*-terminal sequence 
moleculea 
Cycle Amino acid 
Asx 
Thr 
Ser 
Glx 
Pro 
GUY 
Ala 
Val 
Met 
Be 
Leu 
Tyr 
Phe 
Lys 
His 
Trp 
Arg 
Cys 
M, 
13.9 
6.3 
8.1 
22.2 
5.8 
10.1 
8.4 
8.3 
2.4 
5.1 
11.3 
4.2 
4.4 
8.4 
1.4 
,l.3 
13900 
1 X 
2 Val 
3 Arg 
4 Lys 
5 Phe 
6 Thr 
7 Glu 
8 Lys 
9 His 
10 Glu 
11 X 
12 Val 
13 Thr 
14 Thr 
15 lGlu1 
16 IAsp 
17 1GW 
a The amino acid composition of hepatoredoxin was 
determined by duplicate analysis and expressed based 
on an M, of 14000 
Fig.4. The Ouchterlony double-diffusion test. Wells: A, 
antibody to adrenodoxin; 1, hepatoredoxin; 2, 
adrenodoxin; 3, saline. 
Hepatoredoxin 
;(-V.I-Arg-Ly.-Pus-Thr-Glu-L~~-~,~-~~- 
I I 
X-“okThr-Thr-d;u-Asp-Gly- 
Fig.5. Amino acid sequences of NHZ-terminal portions 
of hepatoredoxin a d adrenodoxin. 
4. DISCUSSION 
Hepatoredoxin and adrenodoxin had different 
chemical properties. The amino acid composition 
of the hepatoredoxin differed greatly from 
adrenodoxin, and resembled that of bovine renal 
ferredoxin (renoredoxin) [4,14]. The primary 
structures of hepatoredoxin and adrenodoxin dif- 
fered completely. The NHz-terminal sequences of 
these 2 iron-sulfur proteins are given in fig.5. 
The monomeric molecular mass of hepatoredox- 
in found by electrophoresis was larger than that of 
adrenodoxin. This result was not due to an artifact 
produced with P-mercaptoethanol [151. However, 
the immunochemical precipitin reaction of 
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hepatoredoxin in Ouchterlony double diffusion [5] Ichikawa, Y., Hiwatashi, A., Yamano, T., Kim, 
was similar to that of adrenodoxin. Hepatoredoxin H.J. and Maruya, N. (1980) in: Sixth International 
formed an immunoprecipitin line against antibody Symposium on Flavins and Flavoproteins (Yagi, K. 
to adrenodoxin; the line seemed to be caused by and Yamano, T. eds) pp.677-691, Japan Scientific 
fuse formation. Societies Press, Tokyo. 
The optical absorption spectrum of the 
hepatoredoxin had 2 peaks in the visible region, 
suggesting that hepatoredoxin is of 2Fe-2S type 
1161. 
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